Biography My research interests are in the areas of protein function-structure relationship, protein-protein interactions, and the intervention of protein interactions by antibodies. Current research focuses are recombinant antibody library design, mAb discovery and engineering, immuno-diagnostics and therapeutics. I have worked on projects that include 1) the discovery and engineering of internalizing mAbs targeting basal subtype breast cancer associated membrane proteins for drug delivery, 2) the discovery and engineering of mAbs against serum biomarkers for pancreatic cancer early diagnosis, 3) engineering of antibody Fc to enhance antibody dependent cellular cytotoxicity (ADCC) and pharmacokinetics, 4) the development of host-targeted broad-spectrum anti-viral therapy, 5) the establishment of high-throughput antibody discovery platform, 6) development of therapeutic mAbs to immune-oncological targets, 7) design and construction of recombinant antibody libraries, and 8) impact of germline sequences to antibody developability. The high-throughput antibody discovery is powerful for generating data of antibody-antigen interactions, which can help uncover protein-protein interactions and the de novo design of antibodies. The phage display and yeast display platform allowed identifying mAbs with high affinity and cross-reactivity, can be applied to all immune-oncological targets. Role Faculty Location Zuckerberg San Francisco General Hospital Category Clinical Research Education Post-doc, 03/2004 - Antibody Engineering, UC San FranciscoPh.D., 10/2000 - Protein Engineering, Peking UniversityM.S., 7/1991 - Molecular Biology, Peking UniversityB.S., 7/1988 - Biochemistry, Peking University Publications Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F. Fan Y, Sun Z, Conrad F, Wen W, Zhao L, Lou J, Zhou Y, Farr-Jones S, Marks JD . PloS one . Sep 1, 2022 Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Muller YD, Ferreira LMR, Ronin E, Ho P, Nguyen V, Faleo G, Zhou Y, Lee K, Leung KK, Skartsis N, Kaul AM, Mulder A, Claas FHJ, Wells JA, Bluestone JA, Tang Q . Frontiers in immunology . Sep 20, 2021 Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity. Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, Kumar S, Lulo J, Paragas V, Wong C, Suchy J, Grabow S, Dugast AS, Zhang H, Depis F, Feau S, Jakubowski A, Qiao W, Craig G, Razlog M, Qiu J, Zhou Y, Marks JD, Croft M, Drummond DC, Raue A . Science Translational Medicine . Oct 2, 2019 Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC . Nature biomedical engineering . Apr 5, 2019 Discovery of internalizing antibodies to basal breast cancer cells. Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD . Protein engineering, design & selection : PEDS . Jan 1, 2018 Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5. Le Gall M, Crépin R, Neiveyans M, Auclair C, Fan Y, Zhou Y, Marks JD, Pèlegrin A, Poul MA . Molecular cancer therapeutics . Sep 10, 2015 Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY, Marks JD, Munro T, Mahler SM, Barnard RT, Fromm PD, Silveira PA, Elgundi Z, Ju X, Clark GJ, Bradstock KF, Munster DJ, Hart DN . Leukemia . Aug 19, 2015 A fully human scFv phage display library for rapid antibody fragment reformatting. Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM . Protein engineering, design & selection : PEDS . May 19, 2015 High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. Zhao L, Qu L, Zhou J, Sun Z, Zou H, Chen YY, Marks JD, Zhou Y . PloS one . Oct 29, 2014 Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Li K, Tavaré R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, Marks JD, Wu AM . Molecular cancer therapeutics . Aug 20, 2014 Identifying blood-brain-barrier selective single-chain antibody fragments. Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV . Biotechnology journal . Mar 18, 2014 N-Terminal labeling of filamentous phage to create cancer marker imaging agents. Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB . ACS nano . Aug 6, 2012 Selection and characterization of cell binding and internalizing phage antibodies. Zhou Y, Zhao L, Marks JD . Archives of biochemistry and biophysics . May 22, 2012 Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD . Molecular cancer therapeutics . May 7, 2012 Building and characterizing antibody-targeted lipidic nanotherapeutics. Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC . Methods in enzymology . Jan 1, 2012 Discovery of internalizing antibodies to tumor antigens from phage libraries. Zhou Y, Marks JD . Methods in enzymology . Jan 1, 2012 Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. Zhou Y, Zou H, Zhang S, Marks JD . Journal of molecular biology . Sep 17, 2010 TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M . American journal of translational research . Jul 20, 2010 An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM . European journal of nuclear medicine and molecular imaging . Apr 1, 2010 Identification of target and function specific antibodies for effective drug delivery. Zhou Y, Marks JD . Methods in molecular biology (Clifton, N.J.) . Jan 1, 2009 Development of human single-chain antibodies against SARS-associated coronavirus. Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW . Intervirology . Aug 25, 2008 Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA . Molecular immunology . May 10, 2007 Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD . Journal of molecular biology . May 10, 2007 Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD . Cancer biotherapy & radiopharmaceuticals . Dec 1, 2005
